Inogen (INGN) EVP Matt Scribner Sells 2,500 Shares

Inogen (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $139.79, for a total value of $349,475.00. Following the sale, the executive vice president now owns 8,374 shares in the company, valued at approximately $1,170,601.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Matt Scribner also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, March 15th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $127.95, for a total value of $319,875.00.

Shares of NASDAQ:INGN opened at $143.32 on Wednesday. Inogen has a 12-month low of $75.38 and a 12-month high of $143.63. The company has a market capitalization of $2,957.84, a price-to-earnings ratio of 108.08, a P/E/G ratio of 3.88 and a beta of 1.03.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. Inogen had a return on equity of 13.47% and a net margin of 8.42%. The company had revenue of $63.79 million during the quarter, compared to the consensus estimate of $62.01 million. equities research analysts predict that Inogen will post 1.6 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the business. Louisiana State Employees Retirement System lifted its holdings in Inogen by 7.2% in the fourth quarter. Louisiana State Employees Retirement System now owns 7,400 shares of the medical technology company’s stock valued at $881,000 after acquiring an additional 500 shares during the period. Meadow Creek Investment Management LLC lifted its holdings in Inogen by 26.0% in the fourth quarter. Meadow Creek Investment Management LLC now owns 2,576 shares of the medical technology company’s stock valued at $307,000 after acquiring an additional 532 shares during the period. Congress Asset Management Co. MA lifted its holdings in Inogen by 1.3% in the fourth quarter. Congress Asset Management Co. MA now owns 44,579 shares of the medical technology company’s stock valued at $5,308,000 after acquiring an additional 581 shares during the period. Lenox Wealth Advisors Inc. acquired a new position in Inogen in the fourth quarter valued at approximately $100,000. Finally, LS Investment Advisors LLC lifted its holdings in Inogen by 138.6% in the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock valued at $180,000 after acquiring an additional 880 shares during the period. 98.97% of the stock is owned by institutional investors.

A number of equities research analysts recently commented on the company. Piper Jaffray set a $145.00 target price on Inogen and gave the stock a “buy” rating in a report on Saturday. BidaskClub raised Inogen from a “buy” rating to a “strong-buy” rating in a report on Friday, April 6th. ValuEngine raised Inogen from a “hold” rating to a “buy” rating in a report on Friday, April 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $150.00 target price on shares of Inogen in a report on Tuesday, March 27th. Finally, Zacks Investment Research downgraded Inogen from a “strong-buy” rating to a “hold” rating in a report on Monday, March 5th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $115.14.

COPYRIGHT VIOLATION NOTICE: “Inogen (INGN) EVP Matt Scribner Sells 2,500 Shares” was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://weekherald.com/2018/04/18/inogen-ingn-evp-matt-scribner-sells-2500-shares.html.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply